news

March 10, 2023

Drug development is a perilous process characterized by big risks, large investment (in the order of billions of dollars) and low success rates. The harsh reality is that most investigational drugs (80 90%) do not result in approved medicines. For both drug companies and hopeful patients, this failure rate is daunting. But what if there was a way to improve the ...

press release

February 23, 2023

− Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021 (43% Using Constant Exchange Rate*) – − Submitted and Received Acceptance of Supplemental New Drug Application (sNDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis – − Provides 2023 Combined Net Product ...

press release

January 8, 2023

– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange Rate**) – – Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – – Maintained Strong Balance Sheet with Year End Cash and Investments Balance of Approximately $2.2 Billion – CAMBRIDGE, Mass. ...

press release

December 15, 2022

− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs – − Pipeline Programs and Scientific Innovation Highlighted at R&D Day Exemplify Strength of RNAi Platform and Organic Product Engine – − Alnylam to Webcast its R&D Day Event Today at 8:30 a.m. ET – CAMBRIDGE, ...

capella

December 15, 2022

On December 15, 2022, we hosted a virtual R&D Day event showcasing Alnylam’s late stage clinical efforts, next wave programs, and platform advances. The event included presentations from Alnylam senior leaders as well as guest speakers. To view the webcast, click here To view the R&D Day presentation, click here Speakers: Yvonne Greenstreet, MBChB, MBA – Chief Executive Officer Dr. ...

press release

December 8, 2022

CAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 8, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on December 15, 2022 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the ...

webcast

December 5, 2022

Web Page

November 4, 2022

Our Company DIVERSITY, EQUITY & INCLUSION AT ALNYLAM Harnessing the Power of ANDTM We are proud of our diverse and talented workforce, and it is important that all employees feel they belong and are empowered to achieve their full potential. As a biotechnology leader, it is imperative our R&D processes, clinical trials, and patient advocacy include representation from diverse populations that ...

press release

October 27, 2022

− Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO® – − Strong First Full Quarter of AMVUTTRA in U.S.: Achieving $25 Million in Net Product Revenues and Driving 30% U.S. Total TTR Growth Compared with Q2 2022 – − Reported Positive Results from the APOLLO B Phase 3 Study of Patisiran, and ...

press release

September 19, 2022

– Series Will Culminate in a Virtual R&D Day on December 15, 2022 – CAMBRIDGE, Mass. (BUSINESS WIRE) Sep. 19, 2022 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 9th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer presentations from Alnylam scientists and program ...